Treatment with interleukin-2 in malignant pleural mesothelioma: immunological and angiogenetic assessment and prognostic impact

BACKGROUND: Administration of interleukin-2 (IL-2) has shown some effects on malignant pleural mesothelioma (MPM) tumour regression. The purpose of this study was to investigate the ability of IL-2 to modify immunological effector cells and angiogenesis in MPM patients and their prognostic value. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Alì, G, Boldrini, L, Lucchi, M, Picchi, A, Dell'Omodarme, M, Prati, M C, Mussi, A, Corsi, V, Fontanini, G
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788262/
https://www.ncbi.nlm.nih.gov/pubmed/19935800
http://dx.doi.org/10.1038/sj.bjc.6605438

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788262/
https://www.ncbi.nlm.nih.gov/pubmed/19935800
http://dx.doi.org/10.1038/sj.bjc.6605438

Ejemplares similares